Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 8935 results

  1. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  2. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]

    Awaiting development Reference number: GID-TA11979 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Fertility problems: assessment and treatment - update 1 and 2

    In development Reference number: GID-NG10263 Expected publication date:  31 March 2026

    NICE guideline
    In development

  6. Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation

    In development Reference number: GID-IPG10216 Expected publication date: TBC

    Interventional procedures guidance
    In development

  7. Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma

    In development Reference number: GID-HTG10153 Expected publication date: TBC

    HealthTech guidance
    In development

  8. Technologies to support the rapid diagnosis of endometriosis (provisional title)

    In development Reference number: GID-HTE10082 Expected publication date: TBC

    Health technology evaluations
    In development

  9. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

    NICE guideline
    In development

  11. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over (rapid review of TA1088) [ID6652]

    Awaiting development Reference number: GID-TA11949 Expected publication date:  16 March 2026

    Technology appraisal guidance
    Awaiting development

  12. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over (rapid review of TA1088) [ID6652]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 24 February 2026.

    Technology appraisal guidance
    In consultation

  13. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    7 March 2017

  14. Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

    Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

    Evidence summary
    Published
    14 March 2017

  15. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

    Evidence summary
    Published
    17 March 2015